• AHMED A ABD-RABOU Department of Hormones, Medical Research Division, National Research Centre, 12622, Giza, Egypt.
  • Hanaa h Ahmed Department of Hormones, Medical Research Division, National Research Centre, 12622, Giza, Egypt.
  • Emad f Eskander Department of Hormones, Medical Research Division, National Research Centre, 12622, Giza, Egypt.



 Objective: Clemastine is widely used as an antihistaminic drug. However, clemastine effectively acts as an antagonist of H1 histamine receptor, it has significant burden adverse effects causing common nervous system, psychiatric, and gastrointestinal ailments, as well as rare cardiac and immune system disorders. The objective of this study is to investigate whether there is a remarkable impact of clemastine administration on the human hormonal pituitary-thyroid-adrenal axis.

Methods: To achieve that, hormonal profile was tested in the sera of males and females treated and untreated individuals with clemastine. This is to measure serum estradiol, follicle-stimulating hormone, luteinizing hormone, prolactin, progesterone, dehydroepiandrosterone sulfate, thyroid-stimulating hormone, triiodothyronine, thyroxine, fasting insulin, and cortisol levels. The circulating hormonal levels were measured quantitatively using enzyme-link immunosorbent assay.

Results: We resulted that there were significant differences of the human hormonal profile on clemastine treatment.

Conclusion: Hormonal profiling showed that there were remarkable signatures could be of great interest to underline some recommendations and guidelines optimizing the clemastine dosage to avoid burdens associated with the administration of this drug as well as maintain the physiological and psychological performances of both sexes exposing to clemastine during the period of allergic treatment.

Keywords: Clemastine, H1 histamine receptor, Allergy, Human hormone profile.


1. Sittig M, editor. Pharmaceutical Manufacturing Encyclopedia. 2nd ed. Westwood, NJ: Noyes Publications; 1988.
2. Han S, Karłowicz-Bodalska K, Miśkiewicz K, Kutycka E, Kuchar E. Safety of Oral clemastine - Analysis of data from spontaneous reporting system in Poland. Trop J Pharm Res 2014;13(12):2115-8.
3. Gilman AG, Rall TW, Nies AS, Taylor P, editors. Goodman and Gilman’s the Pharmacological Basis of Therapeutics. 8th ed. New York, NY: Pergamon Press; 1990.
4. Sweetman SC, editor. Martindale: The Complete Drug Reference. London: Pharmaceutical Press, Electronic Version; 2012.
5. Pontiroli AE, Viberti G, Vicari A, Pozza G. Effect of the antihistaminic agents meclastine and dexchlorpheniramine on the response of human growth hormone to arginine infusion and insulin hypoglycemia. J Clin Endocrinol Metab 1976;43(3):582-6.
6. Allolio B, Deuss U, Kaulen D, Winkelmann W. Effect of meclastine, a selective H1 receptor antagonist, upon ACTH release. Clin Endocrinol (Oxf) 1983;19(2):239-45.
7. Abd-Rabou AA, Ahmed HH, Eskander EF. Drug-hormone interference affects pituitary-thyroid-adrenal axis in urinary tract infection. Int J Pharm Clin Res 2016;8(12):1557-63.
8. Eskander EF, Abd-Rabou AA, Ahmed HH. The impact of digestive and colon drugs on the human hormones profile. Indian J Clin Biochem 2013;28(4):413-7.
9. Eskander EF, Abd-Rabou AA, Ahmed HH. Does anti-gout agent allopurinol affect human hormones profile? J Appl Pharm Sci 2013;3(10):79-82.
10. Aizawa S, Sakai T, Sakata I. Glutamine and glutamic acid enhance thyroid-stimulating hormone β subunit mRNA expression in the rat pars tuberalis. J Endocrinol 2012;212(3):383-94.
11. Drummond AH. Chlordiazepoxide is a competitive thyrotropin-releasing hormone receptor antagonist in GH3 pituitary tumour cells. Biochem Biophys Res Commun 1985;127(1):63-70.
12. Novartis Consumer Health Tavegil® Tablets. Summary of Product Characteristics Last Updated on the eMC; 2012. Available from:
13. Izumi N, Mizuguchi H, Umehara H, Ogino S, Fukui H. Evaluation of efficacy and sedative profiles of H(1) antihistamines by large-scale surveillance using the Visual Analogue Scale (VAS). Allergol Int 2008;57(3):257-63.
14. Woroń J, Kostka-Trabka E. Drug interaction and efficiency and safety of pharmacotherapy in otolaryngology. Otolaryngology 2003;2(2):73-8.
15. Woroń J, Porębski G, Obtułowicz K, Korbut R. Drug safety in pharmacotherapy of allergic diseases. Alergol Immunol 2007;4(1-2):22-4.
16. RISK Database; 2012. Available from:
17. Boss M. Lack of effect of the antihistamine drug clemastine on the potentiation of Itch by prostaglandin E1. Arch Dermatol 1981;117(4):208-9.
18. Liu J, Dupree JL, Gacias M, Frawley R, Sikder T, Naik P, et al. Clemastine enhances myelination in the prefrontal cortex and rescues behavioral changes in socially isolated mice. J Neurosci 2016;36(3):957-62.
19. Gupta KR, Askarkar SS. Simultaneous estimation of bepotastine besilate and benzalkonium chloride in ophthalmic formulation by RP-HPLC method. Int J Pharm Pharm Sci 2016;8(6):225-33.
20. Hamed HE, Kamal BA. Preparation and in-vitro evaluation of desloratadine floating tablets. Int J Pharm Pharm Sci 2014;6(9):154-9.
21. Abd-Rabou AA, Zoheir KM, Kishta MS, Shalby AB, Ezzo MI. Nano-micelle of moringa oleifera seed oil triggers mitochondrial cancer cell apoptosis. Asian Pac J Cancer Prev 2016;17(11):4929-33.
22. Abd-Rabou AA, Ahmed HH. CS-PEG decorated PLGA nano-prototype for delivery of bioactive compounds: A novel approach for induction of apoptosis in HepG2 cell line. Adv Med Sci 2017;62(2):357-67.
414 Views | 695 Downloads
How to Cite
AHMED A ABD-RABOU, H. h Ahmed, and E. f Eskander. “CLEMASTINE, THE H1 HISTAMINE RECEPTOR ANTAGONIST, ALTERS THE HUMAN SEX AND THYROID HORMONAL PROFILES”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 10, no. 8, Aug. 2017, pp. 327-30, doi:10.22159/ajpcr.2017.v10i8.19456.
Original Article(s)